Phibro Animal Health (NASDAQ:PAHC) CEO Sells $147,975.03 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 3,651 shares of Phibro Animal Health stock in a transaction dated Wednesday, January 14th. The shares were sold at an average price of $40.53, for a total value of $147,975.03. Following the sale, the chief executive officer owned 47,457 shares of the company’s stock, valued at approximately $1,923,432.21. This represents a 7.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total transaction of $117,338.64.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total transaction of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total transaction of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total value of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total value of $232,425.60.

Phibro Animal Health Trading Up 2.5%

Shares of PAHC stock opened at $41.07 on Friday. The firm has a market capitalization of $1.66 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 1.16 and a beta of 0.79. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $46.42. The firm’s fifty day simple moving average is $40.59 and its 200 day simple moving average is $37.10. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, sell-side analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Investors of record on Wednesday, November 26th were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health’s payout ratio is currently 28.92%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PAHC shares. JPMorgan Chase & Co. lifted their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus target price of $31.40.

Hedge Funds Weigh In On Phibro Animal Health

A number of large investors have recently modified their holdings of PAHC. Financial Management Professionals Inc. bought a new position in Phibro Animal Health in the 2nd quarter worth approximately $32,000. Hughes Financial Services LLC acquired a new stake in shares of Phibro Animal Health in the 3rd quarter valued at $40,000. iSAM Funds UK Ltd acquired a new stake in shares of Phibro Animal Health in the 3rd quarter valued at $61,000. EverSource Wealth Advisors LLC raised its position in shares of Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after acquiring an additional 2,685 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in shares of Phibro Animal Health during the third quarter valued at $96,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.